Several biodegradable sustained-release (SR) device concepts, from drug-eluting contact lenses to lacrimal inserts and intracameral implants, have been put forward in recent years as a means of ...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...
-- Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept -- DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results